ArticleInfection and drug resistance2025
Circulating Outer Membrane Vesicles from Gut-Colonized Carbapenem-Resistant
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Gut colonization of carbapenem-resistant Enterobacterales (CRE) poses a significant risk for systemic infections, but the mechanisms driving resistance dissemination are poorly understood. This study aimed to investigate whether outer membrane vesicles (OMVs) secreted by gut-colonized CRE can enter the human circulatory system and mediate extracellular antibiotic resistance through functional carbapenemases and resistance genes. Patients and Methods: We conducted comparative proteomic analyses of OMVs isolated from parental CRE strains and patient plasma samples. Antibiotic degradation assays were performed to evaluate OMV-mediated hydrolysis of imipenem and meropenem. In vitro experiments assessed the protective effects of OMVs on carbapenem-susceptible Escherichia coli and Pseudomonas aeruginosa. Additionally, a Galleria mellonella infection model was used to examine OMV-mediated bacterial survival under carbapenem pressure. Results: Plasma-derived OMVs exhibited proteomic profiles similar to bacterial OMVs, including carbapenemase components, and demonstrated comparable antibiotic-degrading activity. These OMVs hydrolyzed 60-75% of imipenem and meropenem within 24 hours, protecting susceptible bacteria from growth inhibition in vitro. Although no horizontal gene transfer was observed, OMVs enhanced Conclusion: Our findings reveal a novel OMV-mediated extracellular resistance mechanism that operates independently of genetic transfer, promoting bacterial persistence in the bloodstream. This study provides key insights into the role of OMVs in clinical treatment failure and identifies potential therapeutic targets to combat antibiotic resistance dissemination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.